BB Biotech AG / BB Biotech AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) with the aim of pan-European distribution . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Pursuant to article 26 sec 1 clause 2 WpHG, BB Biotech AG, Schaffhausen, Switzerland, herby reports that it decreased its holding in own shares to below 5% and 3% respectively of the proportion of voting rights as of July 12, 2016 (a total of 280 646 shares / 0.51% of the proportion of voting rights) due to a capital reduction.

All voting rights are held through its wholly-owned subsidiary Biotech Target N.V., Curaçao.

For further information please contact: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht / Zurich

Tanja Chicherio, Tel. +41 44 267 67 00.

Schaffhausen, July 15, 2016

BB Biotech AG

Media release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BB Biotech AG via Globenewswire
HUG#2028669

--- End of Message ---

BB Biotech AG
Schwertstrasse 6 Schaffhausen Switzerland

WKN: 888509;ISIN: CH0038389992;Index:HDAX,MIDCAP,TecDAX,TECH All Share,Prime All Share;
Listed: Regulierter Markt in Frankfurter Wertpapierbörse;